Analysis of serum concentrations of metoprolol and its metabolite alpha-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111517" target="_blank" >RIV/00843989:_____/25:E0111517 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.tandfonline.com/doi/epdf/10.1080/17512433.2025.2450257?needAccess=true" target="_blank" >https://www.tandfonline.com/doi/epdf/10.1080/17512433.2025.2450257?needAccess=true</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/17512433.2025.2450257" target="_blank" >10.1080/17512433.2025.2450257</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Analysis of serum concentrations of metoprolol and its metabolite alpha-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine

Popis výsledku v původním jazyce

Background: The cardioselective ß-1 receptor antagonist metoprolol is used to treat heart failure. It is metabolized in the liver, primarily by cytochrome 2D6. Research design and methods: In this study, trough serum concentrations of metoprolol and its metabolite ?-hydroxymetoprolol were measured in patients with heart failure with reduced ejection fraction. Results: Concentrations were 1.3-122.9 µg/L for metoprolol and 1.3-125.7 µg/L for ?-hydroxymetoprolol, metabolic ratios were 0.11-98.32. The median weight-adjusted apparent clearance of metoprolol was 53.07 (range 3.24-500.0). Metoprolol and ?-hydroxymetoprolol concentrations correlated with both daily dose and dose per kilogram of body weight. However, metoprolol concentrations at the same daily dose showed a wide variability. Patients taking 100 mg/day had significantly lower NT-proBNP values than those taking 25 or 50 mg/day. Patients with LVEF ? 35% versus > 35% used significantly lower daily doses and doses per kilogram of body weight, although metoprolol concentrations did not differ. A poor cytochrome 2D6 metabolizer phenotype was detected in two patients. Conclusions: Metoprolol concentrations showed a wide interindividual variability at the same daily dose. Simultaneous determination of metoprolol and ?-hydroxymetoprolol concentrations could identify patients at risk of possible accumulation of metoprolol leading to intoxication or, conversely, patients at risk of underdosing.

Název v anglickém jazyce

Analysis of serum concentrations of metoprolol and its metabolite alpha-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine

Popis výsledku anglicky

Background: The cardioselective ß-1 receptor antagonist metoprolol is used to treat heart failure. It is metabolized in the liver, primarily by cytochrome 2D6. Research design and methods: In this study, trough serum concentrations of metoprolol and its metabolite ?-hydroxymetoprolol were measured in patients with heart failure with reduced ejection fraction. Results: Concentrations were 1.3-122.9 µg/L for metoprolol and 1.3-125.7 µg/L for ?-hydroxymetoprolol, metabolic ratios were 0.11-98.32. The median weight-adjusted apparent clearance of metoprolol was 53.07 (range 3.24-500.0). Metoprolol and ?-hydroxymetoprolol concentrations correlated with both daily dose and dose per kilogram of body weight. However, metoprolol concentrations at the same daily dose showed a wide variability. Patients taking 100 mg/day had significantly lower NT-proBNP values than those taking 25 or 50 mg/day. Patients with LVEF ? 35% versus > 35% used significantly lower daily doses and doses per kilogram of body weight, although metoprolol concentrations did not differ. A poor cytochrome 2D6 metabolizer phenotype was detected in two patients. Conclusions: Metoprolol concentrations showed a wide interindividual variability at the same daily dose. Simultaneous determination of metoprolol and ?-hydroxymetoprolol concentrations could identify patients at risk of possible accumulation of metoprolol leading to intoxication or, conversely, patients at risk of underdosing.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert review of clinical pharmacology

ISSN

1751-2433

e-ISSN

1751-2441

Svazek periodika

18

Číslo periodika v rámci svazku

1-2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

89-99

Kód UT WoS článku

001398961400001

EID výsledku v databázi Scopus

2-s2.0-85215326767